Patent for Combination of ALT-B4 and Pembrolizumab Composition
Protected Until 2040; Up to 5 Years Additional Protection Possible Through SPC

Alteogen announced on September 23 that its composition patent for a subcutaneous injection formulation combining its hyaluronidase platform 'Hybrozyme'–based ALT-B4 (ingredient name: berahyaluronidase alpha) with Keytruda (ingredient name: pembrolizumab) has been registered with the European Patent Office (EPO).


This patent will be protected until 2040. In consideration of the time required for regulatory approval, it is also eligible for a Supplementary Protection Certificate (SPC), which allows for a maximum extension of up to five years.


Alteogen Headquarters Exterior. Alteogen

Alteogen Headquarters Exterior. Alteogen

View original image

Previously, Alteogen also registered a patent for a Keytruda subcutaneous injection composition in the United States. With the registration of this European patent, the scope of protection for the Keytruda SC composition patent now extends to both the United States and Europe.


Keytruda SC containing ALT-B4 has been gaining regulatory approvals and expanding its market to the United States, Europe, Canada, Korea, and Japan. Recently, Alteogen received the first milestone payment of USD 25 million (approximately KRW 3.38 billion) out of a total of USD 1 billion (approximately KRW 1.3539 trillion) in sales milestones under its contract with Merck & Co., Inc. (MSD) of the United States. Additional milestone payments and royalties are expected depending on future sales performance.



An Alteogen representative said, "Following the United States, we have now secured the composition patent combining ALT-B4 and pembrolizumab in Europe as well. We will continue to secure intellectual property rights for material, composition, manufacturing, and fixed-dose combination patents to underpin stable commercialization."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing